We evaluated whether 4 weeks of pre quit bupropion (extended run-in) results in greater pre quit reductions in smoking rate and cotinine and, secondarily, greater short-term abstinence, than standard 1 week of pre quit bupropion (standard run-in).
Finally, among smokers who failed to quit, smoking reduction occurred more frequently in subjects with high antibody titres ('responders') compared with placebo.
We excluded one study in which participants wanted to quit by reduction, 16 which was included in both the Cochrane and the qualitative reviews.
In line with this suggestion, both women and key informants stressed that smoking by partners, family members and friends deterred quit or reduction attempts and thus conveyed the need for programs and services that target partner and family smoking.
For smokers who have no intention to quit, smoking-reduction interventions may be a therapeutic choice [ 15, 16].
These data indicate little change in mental health from baseline to follow-up in continuing smokers, while smokers who quit showed reductions in adverse mental health symptoms and improvements in positive affect and quality of life.
However few studies have illustrated the mechanism through which such an approach has an influence on quitting or reduction rates among pregnant women in resource poor settings.
'Dropped' means that IDUs quit any harm reduction interventions they were attending.
Some studies found no differences in quit rates or reduction [ 32, 33], whereas others found small to modest effects [ 34- 37].
Nearly half of surveyed American smokers planning to quit would choose reduction over abrupt cessation, and two thirds of these were interested in the assistance of drugs.
Abstinence was defined as not having smoked even once since the day the participant quit after gradual reduction of nicotine intake and pharmacological treatment.
